title: Effects of diacylglycerol ingestion on postprandial hyperlipidemia in diabetes.
abstract: BACKGROUND
  We previously reported that diacylglycerol (DAG) as compared with triacylglycerol (TAG) suppressed increases in postprandial lipids in healthy volunteers. This study was to investigate the effects of DAG on postprandial lipids, particularly remnant lipoproteins in diabetics.
  
  
  METHODS
  Emulsified DAG oil or TAG oil with a fatty acid composition similar to DAG oil was orally administered (30 g fat/m2 of body surface) to moderately controlled six diabetics, with hemoglobin A1c (HbA1c) below 8%, after fasting for at least 12 h in a randomized crossover manner. Serum cholesterol and TAG, lipids in remnant-like particles (RLP), and other lipid parameters including serum ketone bodies were measured prior to and 2, 4, and 6 h after fat loading.
  
  
  RESULTS
  DAG loading significantly suppressed increases in postprandial serum TAG and lipids in RLP as compared with TAG loading. The incremental area under the curve (IAUC) for serum TAG and that for lipids in RLP with DAG loading were also significantly smaller than those with TAG loading. However, changes in serum levels of insulin, free fatty acids, and ketone bodies during fat loading were essentially the same for DAG and TAG.
  
  
  CONCLUSIONS
  This pilot study suggests that substituting DAG intake for TAG may be beneficial to moderately controlled diabetics due to its effect in reducing postprandial hyperlipidemia.
authors.affiliation: Department of Internal Medicine, Division of General Medicine, Kashiwa Hospital, The Jikei University School of Medicine, 163-1 Kashiwashita, Kashiwa, Chiba 277-8567, Japan. n-tada27@jikei.ac.jp
authors.forename: Norio
authors.initials: N
authors.lastname: Tada
authors.forename: Kentaro
authors.initials: K
authors.lastname: Shoji
authors.forename: Masao
authors.initials: M
authors.lastname: Takeshita
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Watanabe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yoshida
authors.forename: Tadashi
authors.initials: T
authors.lastname: Hase
authors.forename: Noboru
authors.initials: N
authors.lastname: Matsuo
authors.forename: Ichiro
authors.initials: I
authors.lastname: Tokimitsu
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D004075:Diglycerides / Q000008:administration & dosage*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000517:prevention & control*; D007328:Insulin / Q000097:blood; D007657:Ketone Bodies / Q000097:blood; D020738:Leptin / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D019518:Postprandial Period
chemical_list: D001786:Blood Glucose; D004075:Diglycerides; D007328:Insulin; D007657:Ketone Bodies; D020738:Leptin; D008077:Lipoproteins, LDL; D017395:Plasminogen Activator Inhibitor 1